Naveris to Highlight New Publications at the 44th Annual J.P. Morgan Healthcare Conference Press Release Naveris to Highlight New Publications at the 44th Annual J.P. Morgan Healthcare Conference
Naveris Announces Expanded Medicare Coverage for the NavDx® Test in Identification of Molecular Residual Disease of Anal Squamous Cell Carcinoma Press Release Naveris Announces Expanded Medicare Coverage for the NavDx® Test in Identification of Molecular Residual Disease of Anal Squamous Cell Carcinoma
Naveris Announces Expansion of the NavDx® Test in Anal Cancer Molecular Residual Disease Surveillance Press Release Naveris Announces Expansion of the NavDx® Test in Anal Cancer Molecular Residual Disease Surveillance
Naveris Announces Expanded Commercial Payor Coverage for NavDx Test from Blue Shield of California Press Release Naveris Announces Expanded Commercial Payor Coverage for NavDx Test from Blue Shield of California
Naveris to Showcase Advances in Precision Surveillance for HPV-Associated Oropharyngeal Cancer Using the NavDx® Test at the 2024 ASTRO Annual Meeting Press Release Naveris to Showcase Advances in Precision Surveillance for HPV-Associated Oropharyngeal Cancer Using the NavDx® Test at the 2024 ASTRO Annual Meeting
Naveris Presents New Data on the NavDx® test for HPV-Associated Oropharyngeal Cancer at the 2024 AAO-HNS Annual Meeting Press Release Naveris Presents New Data on the NavDx® test for HPV-Associated Oropharyngeal Cancer at the 2024 AAO-HNS Annual Meeting
New Multicenter Study Highlights Use of the NavDx® Test in Resolving Clinically Indeterminate Findings Press Release New Multicenter Study Highlights Use of the NavDx® Test in Resolving Clinically Indeterminate Findings
Naveris to Present New Data Highlighting Clinical Utility of the NavDx® Test at the 2024 ASCO Annual Meeting Press Release Naveris to Present New Data Highlighting Clinical Utility of the NavDx® Test at the 2024 ASCO Annual Meeting
Naveris Announces Launch of Phase II Clinical Study in MRD+ Head and Neck Cancer Press Release Naveris Announces Launch of Phase II Clinical Study in MRD+ Head and Neck Cancer
Naveris Awarded ADLT Status by CMS for the NavDx® Test Press Release Naveris Awarded ADLT Status by CMS for the NavDx® Test
